Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation

British Journal of Ophthalmology

Volumn 93, Issue 2, 2009, Pages 159-165

  Tatar, O ^a   Shinoda, K ^b   Kaiserling, E ^c   Claes, C ^d   Eckardt, C ^e   Eckert, T ^e   Pertile, G ^f   Boeyden, V ^d   Scharioth, G B ^g   Yoeruek, E ^a   Szurman, P ^a   Bartz Schmidt, K U ^a   Grisanti, S ^h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b National Hospital Organization   (Japan)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e Augenklinik der Staedtischen Kliniken   (Germany)

^f SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^g Augenzentrum Recklinghausen   (Germany)

^h UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD34 ANTIGEN; CYTOKERATIN 18; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; EYE PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CASE STUDY; CHOROID VASCULARIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; READING; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA TRANSLOCATION; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; RETROSPECTIVE STUDY; SCORING SYSTEM; STROMA; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PIGMENT EPITHELIUM; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; E-SELECTIN; ENDOSTATINS; EYE PROTEINS; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60849126403     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.138594     Document Type: Article

References (49)

1. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. Exp Eye Res 2006;83:329-38.
4. Marneros AG, Keene DR, Hansen U, et al. Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. EMBO J 2004;23:89-99.
5. Takahashi K, Saishin Y, Saishin Y, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 2003;17:896-8.
6. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1544-52.
7. Marneros AG, She H, Zambarakji H, et al. Endogenous endostatin inhibits choroidal neovascularization. FASEB J 2007;21:3809-18.
8. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-20.
9. Shang QL, Ma JX, Wei JS, et al. Experimental choroidal neovascularization is inhibited by subretinal administration of endostatin. Zhonghua Yan Ke Za Zhi 2004;40:266-71.
10. Balaggan KS, Binley K, Esapa M, et al. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther 2006;13:1153-65.
11. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A 2004;101:8005-10.
12. Yeh DC, Bula DV, Miller JW, et al. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci 2004;45:2368-73.
13. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76.
14. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-1522.e14.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
17. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.e5.
18. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
20. Sasano H, Suzuki T. Pathological evaluation of angiogenesis in human tumor. Biomed Pharmacother 2005;59(2 Suppl):334-6S.
21. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;21;8:119-26.
22. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
23. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352- 4.
24. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006;26:354-6.
25. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
26. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
27. Gibran SK, Sachdev A, Stappler T, et al. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 2007;91:602-4.
28. Tatar O, Adam A, Shinoda K, et al. Impact of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008, In press.
29. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-68.
30. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol 2006;124:815-23.
31. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-8.
32. Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3578-85.
33. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3586-92.
34. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
35. Zatterstrom UK, Felbor U, Fukai N, et al. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 2000;25:97-101.
36. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
37. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
38. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
39. Jia YH, Dong XS, Wang XS. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice. World J Gastroenterol 2004;15:10:3361-4.
40. Ergun S, Kilic N, Wurmbach JH, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001;4:193-206.
41. Eriksson K, Magnusson P, Dixelius J, et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003;11:536:19-24.
42. Folkman J. Endogeneous angiogenesis inhibitors. APMIS 2004;112:496-507.
43. Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;15;20:3772-84.
44. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;15;63:8890- 8.
45. Pan X, Wang Y, Zhang M, et al. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 2004;10:1409-14.
46. Tatar O, Shinoda K, Adam A, et al. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Br J Ophthalmol 2007;91:166-73.
47. Tatar O, Shinoda K, Kaiserling E, et al. Early effects of triamcinolone acetonide on VEGF and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-90.
48. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273-80.
49. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93.